Bristol-Myers Squibb announced a strategic AI partnership with Anthropic to deploy Claude across its global workforce, boosting its stock. It also partnered with Tempus AI to improve clinical trials using AI. The company is expanding neuroscience focus after a $14B acquisition, adding schizophrenia and Alzheimer's drugs. New oncology data will be presented at ASCO 2026, highlighting pipeline strength.